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ABSTRACT
Previous scientific data suggests that enterovirus infections, especially those caused by
coxsackieviruses have a role in the pathogenesis of type 1 diabetes. One mechanism by which
viral infection could initiate or accelerate diabetogenic process in humans is ‘molecular mim-
icry’, induction of antiviral immune responses which cross-react with self-epitopes in insulin
producing β-cells. This study was prompted by sequence homology discovered between en-
terovirus capsid/procapsid proteins VP1 and VP0 and two immunogenic diabetes-associated
epitopes in β-cell autoantigens IA-2/IA-2β and HSP60. Possible cross-reactive immune re-
sponses were investigated using proteins and peptides derived from the homologous regions
and extended to sera obtained with immunization with viral proteins and those derived from
viral infections.
Our results showed that rabbit antibodies raised against HSPs recognized capsid protein VP1
of coxsackievirus A9 (CAV9) and coxsackievirus B4 (CBV4) and recombinant VP1 protein of
CAV9.
The results obtained with VP1-, VP0- and IA-2-peptide induced rabbit antisera demonstrated
that immunization of rabbits with these peptides induce cross-reacting immune responses.
Among the cross-reactive immune responses studied, results obtained with coxsackievirus-
derived VP1-peptide and IA-2-peptide induced antisera were most convincing.
Enterovirus induced humoral responses were further studied in rabbits and NOD mice, which
is an animal model for human type 1 diabetes. Both CBV4- and CAV9-induced rabbit antisera
reacted with immunogenic epitope in IA-2. Immunization of female NOD mice with the dia-
betes-associated strain CBV4-E2 resulted in recognition of epitopes in viral capsid proteins.
Epitope mapping with partially overlapping peptides in CAV9 capsid proteins demonstrated
that recognition of both VP0 and VP1 peptide sequences was prominent. Furthermore, epitope
mapping of islet cell autoantigens showed that regions in IA-2 and HSP60, with sequence
similarity with VP1 and VP0, were both recognized by CBV4-E2 immunized NOD mice.
Studies were further extended to humans. Our results indicate that enterovirus infections in
humans may induce immune responses that cross-react with β-cell autoantigens.
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Type 1 diabetes (T1D) is a chronic disease, characterized by progressive destruction of insu-
lin-producing β-cells leading to hyperglycemia and diabetes. According to the most widely
accepted hypothesis, T1D is an autoimmune disease mediated by autoreactive T cells, and is
associated with appearance of autoantibodies to multiple β-cell autoantigens (Gorus et al.,
1997; Leslie et al. 1999).
Type 1 diabetes is thought to be genetically determined disease, associated with HLA mol-
ecules, but in addition, environmental factors are thought to be associated with the pathogen-
esis of T1D.
Enterovirus infections, especially those due to the group B of coxsackieviruses, have long
been suspected of having a role in the pathogenic process (Helfand et al., 1995; Hyöty et al.,
1995; Yoon et al., 1990). The pathway(s) by which enteroviruses may induce or accelerate
diabetes is not well understood. During infection enteroviruses may reach the pancreatic β-
cells and destroy islet cells by cytolysis (Yoon et al., 1979; Szopa et al., 1990). Alternatively,
β-cells could be damaged by virus-induced inflammatory reactions. Furthermore, enterovirus
infection could induce antiviral response that cross-reacts with β-cell autoantigens, leading to
disappearance of normal tolerance to self-antigens and miss-directed immune responses
(Kaufman et al., 1992; Lönnrot et al. 1996).
A great challenge for the future is the better understanding of the mechanism(s) by which vi-
ruses could be involved in the pathogenesis of T1D or in other autoimmune diaseases.
1. INTRODUCTION
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REVIEW OF LITERATURE
1. ENTEROVIRUSES
1.1. The genome of enteroviruses and its expression
Human enteroviruses belong to the family of Picornaviridae and are classified into five sub-
groups, polioviruses (PV), coxsackieviruses A, coxsackieviruses B, echoviruses and enterovi-
ruses 68-71, on the basis of antigenicity and different pathogenity in mice. According to a new
taxonomy, largely based on phylogenetic relationships, human enteroviruses are divided into
five species: PV and human enteroviruses A-D (King et al., 1999) (Table1). Antigenic varia-
tion exists to various degree in all serotypes and even single virus isolates are actually a col-
lection of genetic variants, caused by a high frequency of point mutations and recombination,
which may have pathogenic potential (Rotbart, 1990; Szopa et al., 1990).
The enterovirus genome consists of a single-stranded RNA of positive polarity of about 7500
nucleotides. The genomic RNA acts as a template for viral proteins needed in translation and
replication. The complete viral protein-coding region is translated as a single large
polyprotein, which is proteolytically cleaved to precursors P1, P2 and P3. P1 is cleaved into
three capsid proteins VP0, VP3 and VP1, of which VP0 is cleaved to VP2 and VP4 in capsid
assembly. The virus capsid is formed of 60 copies of each of four capsid proteins VP1-VP4.
Precursor proteins P2 and P3 are further cleaved to seven nonstructural proteins, which have
functions in virus replication and protein processing. The genomic RNA is also used as a tem-
plate for the synthesis of negative strand RNA, which are then used in synthesizing multiple
copies of positive strand RNA. These strands are used in translation of viral proteins, and are
also encapsidated into the assembling virions.
Table 1. New classification of enteroviruses according to King et al. (1999)
Species Serotypes within the species
Poliovirus Poliovirus 1-3
Human enterovirus A Coxsackievirus A 2-8, 10 12, 14, 16
Human enterovirus B Coxsackievirus A9
Coxsackievirus B 1-16
Echovirus 1-7, 9, 11-21, 24-27, 29-33
Enterovirus 69
Human enterovirus C Coxsackievirus A 1, 11, 13, 15, 17-22, 24
Human enterovirus D Enterovirus 68, 70
12
1.2. Clinical manifestations
Outbreaks of enterovirus infections can be worldwide or they can be restricted to small groups
such as schools and day care centers. In temperate climates enteroviruses are most prominent
during the late summer and early autumn. The percentage of different clinical virus isolates
varies depending on the year and country, and clinical isolates do not necessarily predict the
actual prevalence of virus infection. In Finland, according to a study by Hovi et al., (1996),
the CBV5, echovirus 11, CAV9, CBV3 and echovirus 30 predominate in clinical samples.
Enterovirus infection usually starts in the respiratory or gastrointestinal mucosa, spreads
through the lymphatics to the circulation causing viremia and may spread to secondary sites of
replication. A great majority of enterovirus infections are asymptomatic, but they can cause a
variety of diseases from mild upper respiratory infections to poliomyelitis, meningitis, menin-
goencephalitis, myocarditis and skin and mucosal eruptions. Enteroviruses are generally con-
sidered to cause acute infections, but there have been reports indicating the role of enterovirus
in chronic human diseases, some, e.g. myocarditis and autoimmune type 1 diabetes, with au-
toimmune nature (Why, 1995; Åkerblom & Knip, 1998a, respectively).
A widely used serological test of enterovirus infection is the comparision of neutralizing anti-
body titers of acute phase and convalescent phase serum samples. Many seroepidemiological
studies are based on the detection of IgM antibodies by enzyme-linked immunosorbent assay
(ELISA) as evidence of recent enterovirus infection. This method is considered sensitive in
the detection of enterovirus antibodies, but not completely serotype specific (Valtanen et al.,
1999). Several different enteroviral antigens, virus-infected cell lysates, purified virus capsids
and synthetic peptides are used in detection of IgM and IgG antibodies (Cello & Svennerholm,
1994; Frisk et al., 1989; Roivainen et al., 1993a; Samuelson et al., 1987). Detection of IgG
requires, however,  paired serum samples to give proof of recent enterovirus infection.
Molecular biology techniques, especially polymerase chain reaction (PCR) (Hyypiä, 1989), have
greatly improved the detection of viruses in different specimens and are used in diagnosis and
genome comparisons of enteroviruses (Rotbart, 1990).
1.3. Antigenic sites of enteroviruses
Virus infection can induce both B- and T-cell responses. Protective immunity against enterovi-
ruses is created by the presence of serotype specific neutralizing antibodies. Enterovirus infec-
tion induces a rapid production of IgM, followed by IgG and IgA class antibodies. IgM antibod-
ies usually disappear in 6 months, while IgG and IgA can  persist for years. Apart from neutraliz-
ing antigenic sites there are other antigenic regions that induce immunity, but are not neutraliz-
ing and they often induce cross-reacting immune responses (Hovi & Roivainen, 1993).
Many B-and T- cell epitopes in various enteroviruses have been characterized (Huber et al.,
1993b; Mahon et al., 1992; Roivainen et al., 1991; Simons et al., 1993). Most B-cell epitopes
13
are thought to be conformational, while T cells recognize shorter, usually linear peptides
(Horsfall et al., 1991). Antigenic determinants of enteroviruses have been investigated in hu-
mans, in mice by infection or immunization with enterovirus, and in rabbits by immunization
with viruses (Huber et al., 1993a; Pulli et al., 1998; Roivainen et al., 1991). Targets of hu-
moral antigenic responses have been studied with escape mutants generated by neutralizing
monoclonal antibodies (Minor et al., 1986), with synthetic overlapping peptides and peptide
scanning method (Pulli et al., 1998; Roivainen et al., 1991).
The major neutralizing antigenic sites in polioviruses exist in VP1, and to a lesser extent in
VP2 and VP3 (Hogle et al., 1985; Mateu, 1995; Rossmann et al., 1985). By the peptide scan-
ning techinique, the most reactive humoral epitopes in PV3 were in VP1 and VP3 capsid pro-
teins, while none were found in the VP4 protein (Roivainen et al., 1991).
Antigenic sites in other enteroviruses are less well known. Some information has been pub-
lished on antigenic sites in CAV9, CBV4 and CBV3. Antisera raised against native CAV9 in
rabbits recognized epitopes in VP2 and VP3 and three regions in VP1 (Pulli et al., 1998).
Polyclonal antisera raised against CBV3-derived peptides also recognized VP1, VP2 and VP3
capsid proteins (Auvinen et al., 1993).
Enterovirus-specific T-cell epitopes have been analyzed in mice inoculated or infected with PV
or CBV3, and investigated by proliferation of lymphocytes to peptides (Huber et al., 1993;
Mahon et al., 1992). Most T-cell epitopes were identified to localize in VP1 and VP3 proteins.
Some PV epitopes were serotype specific, located usually in VP1 and VP3, while cross-reactive
T-cell epitopes were located in VP4 (Mahon et al., 1992). Enterovirus infection in humans has
been shown to induce both serotype specific and cross-reactive immune responses (Cello et al.,
1996; Graham et al., 1993; Juhela et al., 1998). T-cell epitopes in VP1 protein of PV1 and PV3
were shown to exist near neutralizing antigenic sites (Graham et al., 1993; Simons et al., 1993).
Studies by Simons et al. (1993) showed that isolated peripheral blood lymphocytes from OPV-
vaccinated humans respond to all isolated capsid proteins VP1-VP4. VP2 and VP3 and to a
lesser extent VP1 were shown to contain T-cell epitopes by Cello et al.(1996). In a recent study,
a panel of CBV4-specific T-cell lines were generated and their target epitopes were shown to be
concentrated in regions, which are conserved among enteroviruses (Marttila et al., 2002), con-
firming the earlier reports (Cello et al., 1996; Juhela et al., 1998) showing that T-cell epitopes
are largely cross-reactive between various enterovirus serotypes.
2. TYPE 1 DIABETES (T1D)
Type 1 diabetes mellitus (T1D), or insulin-dependent diabetes (IDDM), is thought to be an
autoimmune disease characterized by progressive destruction of insulin-producing β-cells of
the Langerhans islets, most probably by autoreactive T lymphocytes directed against islet cells
or their antigenic determinants (Atkinson & Maclaren, 1994). Only very rarely, disease devel-
ops abruptly and without characteristic immune markers. The β-cell destruction progress is
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gradual, and it can take years before clinical presentation of diabetes, when about 80% of cells
are already destroyed (Figure 1). Islet cell autoantigens are largely studied by investigation of
specificities of circulating antibodies present in sera and PBMC derived from diabetic and
prediabetic individuals (Figure 1). Considerable progress has been made in the identification
of T1D associated antigens, such as ICA (Bottazzo et al., 1974), GAD65 (glutamic acid decar-
boxylase) (Baekkeskov et al., 1990), insulin (Palmer et al., 1983; Palmer, 1987), tyrosine
phosphatase IA-2 (or ICA512) and IA-2β (or IARββ, phogrin) (Christie et al., 1992; Cui et
al., 1996; Hawkes et al., 1996; Lu et al., 1996; Payton et al., 1995), heat shock proteins (Birk
et al., 1996; Elias et al., 1990; Jones et al., 1990), ICA69 (Pietropaolo et al., 1993), and
GLIMA (Aanstoot et al., 1996).
Figure 1. Phases of T1D pathogenesis
2.1. Insulitis
A common histopathological feature associated with the development of T1D is insulitis,
characterized by the presence within and around the islets of mononuclear cells consisting
mainly of T lymphocytes and macrophages (Bottazzo et al., 1985; Foulis et al., 1986), and a
high proportion of the lymphocytes has been shown to secrete IFNγ (Foulis et al., 1991). Hu-
man studies are largely confined to autopsies on patients who have died of recent onset diabe-
tes, and most of the work in humans has been done using peripheral blood cells, although they
do not necessarily represent the infiltrate very good.
                                     
100 %
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15
Much of our knowledge on the pathogenesis of T1D in humans is interpolated from studies on
non-obese diabetic (NOD) mice, an animal model for human T1D. Many genetic and immu-
nological features, like pancreatic infiltrates and β-cell specific autoantibodies, are similar to
those in human disease. In NOD-mice the development of diabetes is, however, spontaneous
and female mice develop insulitis early in life (2-4 weeks) and develop overt diabetes from 12
weeks on. The incidence of diabetes varies between colonies (Pozzilli et al., 1993), but typi-
cally 70-80% of female NOD-mice are diabetic by 30 weeks of age. As in human T1D, there
is extensive infiltration of islets by T cells, macrophages, B cells and dendritic cells
(Chatterjee et al., 1992; See & Tilles, 1995).
2.2. Contribution of genetics to T1D
The susceptibility to T1D is thought to be determined by a combination of genetic and envi-
ronmental factors. Twin studies, family studies, and animal models have helped to elucidate
the genetics of autoimmune diabetes. The prevalence of type 1 diabetes is highest in identical
twins (about 30-50%) decreasing to 16-20% in HLA identical siblings (Cavender et al., 1984;
Tarn et al., 1988). The risk in the general population is 0.3-0.7% (Bingley et al., 1993; Tillil &
Kobberling, 1987).
Most of the genetic susceptibility is accounted for by human leukocyte antigen HLA alleles on
chromosome 6. HLA class I molecules are composed of α-chain and β2-microglobulin that
are expressed on all nucleated cells and which present antigenic peptides to cytotoxic CD8+ T
cells. The HLA class II molecule is also a heterodimer, composed of one α and one β
chain, and they are expressed on antigen presenting cells (APC). HLA II molecules present
antigenic peptides to CD4+ T cells. Allelic variations in the binding pocket among HLA mol-
ecules accounts for differences in peptides preferentially bound by each class II molecule
(Kwok et al., 1996; Reijonen et al., 1991; Todd et al., 1987). Susceptible alleles may select
potential autoreactive T cells during thymic selection, while protective/neutral alleles may ei-
ther delete or fail to select these potential autoimmune T cells, thus reducing the possibility of
developing disease. In the periphery, an HLA molecule derived from a susceptible allele may
then recognize and present self peptide, or foreign peptide that cross-reacts with an
autoantigen, leading to activation of autoreactive T cells. DQB1 and DRB1 are considered the
most important genes in either protection or susceptibility to T1D (Awata et al., 1992; Ilonen
et al., 1997; Karvonen et al., 1993).
2.3. Role of immunopathology in T1D
There is a lot of evidence that many different sectors of the immune system take part in initia-
tion and progression of β-cell destruction: presentation of antigens by HLA I and II mol-
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ecules, proliferation of CD4+ T cells specific for different cell autoantigens (Durinovic-Bello
et al., 1996; Harrison et al., 1992; Roep, 1996), stimulation of β-cell specific autoantibodies,
activation of cytotoxic CD8+ T cells, recruitment of inflammatory cells and the production of
cytokines. The availability of NOD-mice has greatly enhanced the understanding of the pos-
sible pathogenic mechanisms involved in human T1D. With the possibility of separating dif-
ferent cell types or blocking their activity it has been possible to investigate the roles of CD8+,
CD4+, B cells, cytokines and β-cell autoantigens in the development of diabetes.
The exact mechanism involved in the initiation and progression of β-cell destruction and the
main component of immune system, having the major role in the destruction process, is unre-
solved (Yoon et al., 1998). Most probably T1D results from a dysregulation in humoral and
cell-mediated immunity (Atkinson & Maclaren, 1994).
2.3.1. Cellular immune reactions in T1D
Strong evidence of the role of T cells in the pathogenesis of T1D comes from studies with
NOD-mice, where diabetes can be transferred with T lymphocytes from diabetic mice into
irradiated recipients (Elias et al., 1990; Kaufman et al., 1993; Wicker et al., 1986). Moreover,
there are plenty of examples of prevention of diabetes in NOD-mice including suppression of
T-cell autoimmunity (Elias et al., 1991; Kaufman et al., 1993; Lampeter et al., 1989; Tisch et
al., 1994; Zechel et al., 1997). Studies with immune suppressive agents, and those involving
the development of diabetes in recipients after bone marrow transplantation from T1D patient
(Lampeter et al., 1993), together with numerous studies of T-cell responses in diabetic patients
to islet cell autoantigens, indicate that cellular immune responses are important in the patho-
genesis of human T1D. (Eisenbarth, 1986; Honeyman et al., 1998; Lampeter et al., 1993;
Roep, 1996).
In NOD-mice it has been shown that both CD4+ and CD8+ subsets of T cells play a role in de-
velopment of disease. The absence of CD4+ T cells prevented diabetes in NOD-mice (Phillips
et al., 2000; Shizuru et al., 1988). Diabetes did not occur in CD8+ deficient mice either (Katz
et al., 1993; Serreze et al., 1994; Wang et al., 1996). Controversies, however exist, and ac-
cording to one group, CD4+ T cells, but not CD8+ have been shown to alone transfer disease
(Christianson et al., 1993), while Wong 96 et al. (1996) reported that transfer of CD8+ T-cell
clones from young NOD islets can cause rapid onset of diabetes in NOD-mice in the absence
of CD4 cells.
CD4 cells are further divided into Th1 and Th2 types based on the cytokines they secrete. Th1
cytokines are classified as inflammatory cytokines. Secretion of these cytokines results in
upregulation of MHC molecules on APC, enhancement of CTL killing, increased activation-
induced cell death and proliferation, and recruitment of other cells that secrete Th1 cytokines
(Mauricio & Mandrup-Poulsen, 1998; von Herrath & Oldstone, 1997). Th2 cells secrete IL4,
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IL5, IL6, IL10 and IL13 and provide help for B-cell activation and for antibody production.
Artificial introduction of cytokines or antibodies to cytokines that favor Th1 or disfavor Th2
cell development generally promotes diabetes, whereas the converse inhibits diabetes (Katz et
al., 1995; Sarvetnick et al., 1990; Trembleau et al., 1995).
2.3.2.  Humoral immune responses in T1D
Antigen presenting cells, B lymphocytes, dendritic cells (DC), and macrophages have all been
shown to take part in insulitis and T1D in rodents, and the removal of B cells reduces or pre-
vents diabetes  (Akashi et al., 1997; Serreze et al., 1996; Wong et al., 1998). Serreze et al.
(1998) later, showed that the diabetogenic role for the B lymphocytes in NOD-mice is based
on the abilty of B cells to process and present certain β-cell autoantigens to autoreactive T
lymphocytes. Trembleau et al. (2000) showed that T-cell response to IA-2 represents an early
event in T1D in NOD-mice, as in humans, and conclude that autoantibodies to IA-2 in hu-
mans do not only reflect destruction of β-cells by exposed intracytoplasmic IA-2, but that B
cells producing these autoantibodies have obtained help from pathogenic T lymphocytes
(Trembleau et al., 2000).
Antibodies to several β-cell antigens found in circulation is the most evident sign of β-cell
autoimmunity, and they are used for assessing the risk for type 1 diabetes and in the search for
the cause of the disease. Antibodies can have direct effector functions, and they may play a
significant role in the processing and presentation of T-cell epitopes to T cells. Antibodies
have been shown to increase the efficiency of antigen capture by APCs, and antigen-antibody
complexes can substantially lower the amount of antigen needed to stimulate T-lymphocyte
response (Amigorena & Bonnerot, 1998). This is supported by Reijonen et al., (2000), who
showed that GAD65-specific autoantibodies enhance the presentation of GAD65 to T cells
and the enhancement was most prominent with sera from patients with high GAD65 antibody
levels.
2.4. Target antigens
Much research has focused on identifying key antigen(s) initiating the immunological reac-
tions leading to β-cell specific autoimmune responses. Although yet unidentified, β-cell
autoantigens were shown to be important in development of diabetes and autoreactive T lym-
phocytes able to transfer diabetes in NOD-mice require the presence of target β-cells (Larger
et al., 1995). Islet cell autoantigens are largely studied by investigation of specificities of cir-
culating antibodies present in sera and PBMC derived from diabetic and prediabetic subjects.
Of several islet cell autoantigens described (Baekkeskov et al., 1990 ; Birk et al., 1996; Cui et
al., 1996; Elias et al., 1990; Jones et al., 1990; Palmer, 1987; Pietropaolo et al., 1993) insulin,
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GAD65, IA-2 and HSP60 (especially in NOD mouse) seem to be most relevant.
Inter- and intramolecular spreading of both B- and T-cell autoimmune responses has been
shown to occur both in humans (Bonifacio et al., 2000; Brooks-Worrell et al., 2001;
Durinovic-Bello et al., 1996; Sohnlein et al., 2000) and NOD-mice (Tian et al., 1996; Tisch et
al., 1993; Zechel et al., 1998b) and is associated with a greater risk for developing type 1 dia-
betes (Brooks-Worrell et al., 2001; Durinovic-Bello et al., 1996;  Kawasaki et al., 1998; Knip,
1998b).
2.4.1. ICA
Identification of autoantibody-positive individuals relied previously on histochemical detec-
tion of islet cell-specific autoantibodies (ICA) on frozen sections of human pancreas
(Bottazzo et al., 1974). High and persistent levels of ICA have been shown to predict the de-
velopment of type 1 diabetes (Bonifacio et al., 1990; Knip et al., 1994), especially in sibling
pairs of affected individual with type 1 diabetes (Knip et al., 1998b). ICA comprise autoanti-
bodies to a number of antigens, of which GAD65 and IA-2 autoantibodies represent the major
fraction. Screening for these two protein antibodies is suggested to replace ICA testing in fu-
ture (Gorus et al., 1997; Kulmala et al., 1998).
2.4.2. GAD65
Immunoprecipitation with radiolabelled human islet cell extracts identified 65 kDa proteins as
major targets for autoantibodies in T1D (Baekkeskov et al., 1990), later identified as glutamic
acid decarboxylase (GAD65), which catalyzes the synthesis of the inhibitory transmitter γ-
aminobutyric acid (GABA). There are two isoforms of GAD, GAD65 and GAD67, which are
mainly expressed in pancreatic β-cells and the central nervous system. Human islets predomi-
nantly express GAD65, while in mouse islets GAD67 appears to dominate (Kim et al., 1993).
Antibodies to GAD65 are detected in vast majority of T1D patients at the diagnosis of disease
and in the preclinical phase (Bonifacio et al., 2000; Seissler et al., 1992;  Verge et al., 1994).
Anti-GAD autoantibodies have been studied in relatives of T1D patients (Kulmala et al., 1998)
and GAD antibodies, combined with detection of both insulin and IA-2 antibodies, identify a
large proportion of individuals at risk and nearly all patients with T1D (Verge et al., 1998). The
major humoral antigenic regions of GAD antibodies (GADA) seem to be directed to the middle
and C-terminal part of GAD65 (Hawa et al., 2000; Leslie et al., 1999; Richter et al., 1993).
T-lymphocytes derived from diabetic patients have been shown to react with GAD65 proteins
and various peptides within the protein (Atkinson et al., 1994; Endl et al., 1997; Harrison et
al., 1993; Lohmann et al., 1994; Lohmann et al., 1996). T cells from T1D patients have been
reported to respond immunodominately to peptide 247-279 in GAD65, which show sequence
homology expanding six amino acids (PEVKEK) with coxsackievirus 2C protein (Atkinson et
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al., 1994). These finding were not, however, confirmed by Lohmann et al. (1994) and Schloot
et al. (1997) whose results showed that reaction to this homologous peptide is not primarily
associated with T1D.
The importance of GAD-induced immune responses in the development of diabetes and the
epitopes eliciting these responses have been intensively studied in NOD-mice (Kaufman et
al., 1993; Zechel et al., 1998a). The Th1 response to GAD was shown to develop in NOD-
mice at the time of onset of insulitis (Kaufman et al., 1993) and GAD expression in the islet
cells was shown to be essential for induction of diabetogenic T-cells (Yoon et al., 1999). Fur-
thermore, diabetes could be prevented by intrathymic or intravenous immunization of young
NOD-mice with purified GAD65, GAD67 or peptides derived from these proteins (Kaufman
et al., 1993; Tian et al., 1996; Tisch et al., 1993, 1994, 1999). Intraperitoneal injection of
GAD65 at 8 weeks of age, even after the onset of insulitis, was able to inhibit disease progres-
sion (Tian et al., 1996) and moreover, GAD65 also prevented the development of other immune
reactions that usually occur in NOD-mice, such as those against HSP65. The mechanism of pro-
tection seems to involve activation of Th2 cells, which home to the islets and secretion inhibi-
tory cytokines (Tian et al., 1996, 1998; Tisch et al., 2001). Anti-GAD antibodies have been de-
tected also in NOD-mice but not all studies confirm this result (Bonifacio et al., 2001).
2.4.3. IA-2/IA-2β
Sera of T1D patients were shown to immunoprecipitate 40 –and 37-kDa  tryptic fragments
from islet-cell lysates (Christie et al., 1990, 1993). These fragments were later identified to
encompass most of the cytoplasmic domain of two protein tyrosine phosphatase (PTP) like
proteins IA-2 (IA-512) and IA-2β (phogrin, IAR), which share a high degree of sequence
homology in their intracellular part (Bonifacio et al ., 1995; Cui et al., 1996; Hawkes et al.,
1996; Lu et al., 1996; Payton et al., 1995). These are transmembrane proteins primarly ex-
pressed in secretory granule membranes of Langerhans islet cells and in many parts of the
central nervous system (Solimena et al., 1996). Although IA-2 and IA-2β are members of PTP
family, their have not been shown to have enzymatic activity and the function of native pro-
teins is not known.
Many patients with type 1 diabetes have autoantibodies to IA-2 (Ellis et al., 1998; Hawa et al.,
2000; Kawasaki et al., 2001; Seissler et al., 1996; Verge et al., 1996) and antibodies are directed
to intracellular part of the protein. Antibody prevalences as high as 86% have been detected in
T1D patients at and prior to disease onset  (Savola et al., 1998) and they seem to be more
prevalent in younger patients and in patients with HLA DR4 haplotype (Genovese et al., 1996),
and they have a high positive prediction value for type 1 diabetes (Gorus et al., 1997).
The major humoral antigenic determinants of both IA-2 and IA-2β reside in the C terminus,
but antibodies are also directed to the N-terminal and middle regions of cytoplasmic IA-2
(Bonifacio et al., 1998; Kolm-Litty et al., 2000; Leslie et al., 1999; Seissler et al., 2000). The
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use of IA-2 deletion mutants and chimeric proteins showed determinant spreading and changes
in epitope specificity during disease progression (Kawasaki et al., 1998; Park et al., 2000)
Peripheral blood T-lymphocytes from patients with type 1 diabetes have been shown to react
with IA-2 (Durinovic-Bello et al., 1996). Diabetes-associated T-cell epitopes within intracellu-
lar part of IA-2 have been characterized by some groups either with the use of synthetic pep-
tides or by elution of peptides from the T1D-associated HLA-DR4 molecule (Hawkes et al.,
2000; Honeyman et al., 1998; Peakman et al., 1999).
Recently, identification of T-cell responses to the intracellular part of IA-2 was reported in
unprimed NOD-mice, detected already in 3-week-old mice by increased production of INF-γ
(Trembleau et al., 2000). They also showed that intraperitoneal (i.p.) injection of IA-2 into 8-day
old mice significantly enhanced T1D development. T-cell clones with diabetogenic activity have
also been generated from young female NOD-mice immunized with cytoplasmic region of 
recombinant phogrin , and some of these T-cell clones destroyed islet tissue in vivo (Kelemen et al.,
1999). Two main T-cell epitopes in phogrin were identified by the same group using recombi-
nant phogrin deletion mutants and overlapping peptides (Kelemen et al., 2001).
Low levels of IA-2 specific antibodies in the sera of NOD-mice were directed to cytoplasmic
domain of IA-2 and were usually transient and noticed before the onset of hyperglycemia
(Myers et al., 1998). Reports on humoral responses to IA-2 antigens in NOD-mice are, how-
ever, controversial (Bonifacio et al., 2001).
2.4.4. Insulin
Insulin and its precursor proinsulin are the only known β-cell specific autoantigens so far
identified. Insulin is a 5.8 kDa protein hormone, which is synthesized from a   prehormone,
proinsulin, consisting of A-and B-chains and a C-peptide, which is proteolytically cleaved off
to produce the mature protein. Antibodies to insulin are detected in 16-70% of newly diag-
nosed T1D patients (Palmer et al., 1983; Sabbah et al., 1999) and they are often the first anti-
bodies to appear (Ziegler & Eisenbarth, 1990). T-cell responses to insulin have been more dif-
ficult to demonstrate in diabetic patients (Durinovic-Bello et al., 1996), but there are reports
indicating cellular responses to insulin (Keller, 1990; Schloot et al., 1998).
T cells from β-cell infiltrates of NOD have been shown to be specific for insulin and most of
them recognized B-chain peptide B9-23 (Daniel & Wegmann, 1996; Wegmann & Eisenbarth,
2000). Moreover, insulin specific Th1 CD4+ T-cells can transfer the disease to NOD-scid mice
(Daniel et al., 1995). In another study, CD8+ T- cells that transferred diabetes were shown to
recognize the insulin B-chain residues 15-23 (Wong et al., 1999). The role of insulin in the
development of diabetes is further suported by studies in which the administration of insulin,
insulin B-chain, or an insulin peptide epitope was able to significantly delay or protect against
diabetes in NOD-mice (Daniel & Wegmann, 1996, Hutchings & Cooke, 1998). Hutchings et
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al (1998) also showed that the protection is dependent on the route of insulin administration
(Hutchings & Cooke, 1998). Accumulating evidence suggests that proinsulin may be an im-
portant autoantigen in type 1 diabetes (Bohmer et al., 1991; Chen et al., 2001; Congia et al.,
1998; Dubois-LaForgue et al., 1999). When transgenic mice expressing HLA-DR4 and human
CD4 molecule were immunized with human preproinsulin, (PPI), proinsulin (PI), and insulin,
it was shown that the main T-cell epitopes reside in preproinsulin-and proinsulin regions span-
ning part of the leader sequence and B-chain and another spanning C-peptide and A-chain
(Congia et al., 1998).  Both the leader and the C-peptide are cleaved off from the precursor to
give mature insulin. Chen et al. (2001) showed that proinsulin autoreactive T-cells are de-
tected in young unprimed NOD-mice, and T-cell responses are mainly directed against proin-
sulin p24-33 epitope that spans the B-chain/C-peptide junction. These data are consistent with
the notion that T-cell reactivity to mature insulin is rare in T1D (Durinovic-Bello et al., 1996).
The data presented by the International Workshop on autoantibodies in animal models of T1D
(Bonifacio et al., 2001) demonstrated that insulin autoantibodies are markers of autoimmunity
in NOD-mice, and they appear in10-30% of mice at the age of 4 weeks and in 15-75% at the
onset of diabetes.
2.4.5. HSP
Heat shock proteins (HSP) belong to a family of related proteins, which are inducible in re-
sponse to stressful stimuli and/or constitutively expressed by prokaryotic and eukaryotic cells
(Lindquist & Craig, 1988). HSP60 is expressed with insulin in the secretory granules of β-
cells and its distribution within the β-cell has been shown to vary in prediabetic NOD-mice
and is temporarily associated with the induction of humoral response to HSP60 (Brudzynski et
al., 1992; Brudzynski, 1993).
The critical role of immunity against HSP60 in NOD mouse diabetes was shown by Cohen
and coworkers, who discovered that NOD-mice spontaneously develop autoantibodies and
autoreactive T-cells to the autologous HSP60 (Birk et al., 1996; Elias et al., 1991), a molecule
that cross-reacts with the 65 kDa heat shock protein (HSP65) of Mycobacterium tuberculosis
(Elias et al., 1991; van Halteren et al., 2002). The 437-460 peptide sequence of HSP60, desig-
nated p277, was found to serve as an important target in mouse type 1 diabetes. T-cells reac-
tive to p277 were capable of transfering diabetes, and modulation of the anti-HSP60 T cell
response could arrest the autoimmune destruction of β-cells (Elias & Cohen, 1994; Elias et
al., 1990, 1991, 1997). Even a single subcutaneous administration of peptide 277, given late
in the autoimmune process, could induce a shift in the cytokine profile of activated T-cells
from Th1 type to anti-inflammatory Th2 type (Ablamunits et al., 1998, Elias & Cohen, 1995;
Elias et al., 1997).
Studies investigating the role of HSP60 in human type 1 diabetes are fewer. Increased T-cell
responses to intact human HSP60 and to peptide p277 were significantly increased in patients
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with type 1 diabetes patients compared with the type 2 group and healthy blood donors
(Abulafia-Lapid et al., 1999). Recently, two regions in HSP60 and HSP65/M.Bovis were rec-
ognized by diabetic patients’ sera using epitope scanning (Horvath et al., 2002). The first re-
gion, aa 394-413 and aa 366-385 in HSP60 and HSP65 in M. Bovis, respectively, is similar to
the sequence aa 520-534 found in GAD65 (Jones et al., 1993). The second reactive region
overlaps with p277 to a large extent HSP60 aa 435-454 and HSP65/M.Bovis aa 408-427. In-
teresting results were recently published from a randomized, double-blind, phase II study
where patients with newly diagnosed T1D were treated with of HSP p277 (Raz et al., 2001).
The group showed that patients who had received p277 maintained their ability to produce C-
peptide and needed significantly less exogenous insulin compared to patients in the placebo
group. The mechanism was thought to be an epitope-specific shift from Th1 to Th2 cytokine
production by autoimmune cells.
2.5. Environmental factors
Several lines of data support the role of environmental factors in the pathogenesis of type 1
diabetes. First, the concordance rate for T1D in monozygotic twins is less than 50%
(Cavender et al., 1984). Second, epidemiological data and seasonality of the disease indicate
the contribution of external factors in T1D. Incidence varies even 10-fold within Europe, more
than can be expected due to genetic differences in populations and the incidence is increasing
rapidly both in low- and high-incidence populations, being highest in Finland (Onkamo et al.,
1999). The strongest putative contributors among the environmental factors in T1D are nutri-
tional factors and viral infections.
2.5.1. Dietary factors
Nutrition, particularly animal proteins and nitrosamines in the diet have been considered as
putative factors in T1D (Åkerblom & Knip, 1998). Enhanced immune responsiveness against
several cow milk proteins, such as bovine serum albumin (BSA) and β-lactoglobulin, has
been reported in type I diabetic patients (Karjalainen et al., 1992; Vaarala et al., 1996). One
possibility is that milk proteins induce cross-reactive responses to β-cell autoantigens based
on sequence similarities between milk proteins and autoantigens (Karjalainen et al., 1992). On
the other hand, cow’s milk formulas might induce humoral immunity to bovine insulin, with
subsequent cross-reaction with human insulin (Vaarala et al., 1999).
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2.5.2. Enteroviruses
2.5.2.1. Epidemiological data
Enteroviruses, especially those belonging to coxsackieviruses, have for long been suspected of
having a role in the pathogenesis of T1D (Banatvala et al., 1985; Yoon, 1990; Yoon et al.,
1979). By seroepidemiological studies several enteroviruses have been associated with type 1
diabetes (Hyöty et al., 1995; Roivainen et al., 1998; Sadeharju et al., 2001). Increased preva-
lence and elevated levels of enterovirus IgM antibodies and enterovirus RNA have been re-
ported in newly diagnosed type 1 diabetic patients (Clements et al., 1995; Helfand et al.,
1995), implying that enterovirus infection could be a final hit in disease progression. The pos-
sible initiating role for enteroviruses in β-cell destruction was investigated in a prospective
study carried out in Finland (Hyöty et al., 1995). This study showed that enterovirus infections
were more common both close to the time of diagnosis and even years before clinical presen-
tation of the disease in children who later developed type 1 diabetes when compared to chil-
dren who remained non-diabetic over the follow-up period. Enterovirus infections appeared to
coincide with seroconversion or enhancement of immune responses to islet cell or insulin an-
tibodies (Hiltunen et al., 1997; Hyöty et al., 1995; Lönnrot et al., 2000).
A few studies of the T cell responses to enterovirus antigens have been published (Bruserud et
al., 1985; Jones & Crosby, 1996b; Juhela et al., 2000). Results by Jones et al. (1996) and
Juhela et al. (2000) indicate that patients with type 1 diabetes have stronger T-cell responses
to CBV-infected cell lysates, whereas Bruserud et al. did not find a difference in T-cell re-
sponses to CBV4 antigen. HLA background may influence the host’s susceptibility or resis-
tance to EV infections (Bruserud et al., 1985; Luppi et al., 1999). This is supported by the
study where seroconversion to ICA after enterovirus infection was seen more often in children
with the high risk HLA-DQB1 genotype (Hiltunen et al., 1997).
2.5.2.2.  Studies in mice
Yoon et al., (1979) reported of 10-year-old boy who had diabetic ketoacidosis days after hav-
ing flu-like symptoms, and who died a few days later. Coxsackie B4 virus could be isolated
from the pancreas and the isolate was shown to induce hyperglycaemia, inflammation in the
islets of Lagerhans and β-cell necrosis in mice (See & Tilles, 1995; Szopa et al., 1993; Yoon
et al., 1979). Although the nucleotide sequence of this CBV4-E2 has been determined (Kang
et al., 1994), the pathogenic determinants have not been reported. According to one study,
mice that developed severe disease were more immunoresponsive than mice that survived in-
fection with CBV4, suggesting that immunomediated mechanism may play a role in the sever-
ity of CBV4-induced disease (Halim & Ramsingh, 2000).
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2.6. Possible mechanisms of β-cell destruction by viruses
Viruses may play a role at various stages of T1D pathogenesis. They may initiate the process
in individuals with no previous β-cell damage, accelerate an already ongoing process, or be
the final hit precipitating the symptoms of T1D. The mechanism(s) by which enteroviruses
may trigger autoimmunity and onset of type 1 diabetes are not clear. First, enterovirus infec-
tion in the pancreas may cause direct β-cell lysis by the cytotoxic life cycle of the virus (Szopa
et al., 1990). Second, viral infection may induce a systemic immune response that cross-reacts
with β-cell autoantigens (molecular mimicry) (Atkinson et al., 1994; Vreugdenhil et al.,
1998). Furthermore, viral infections result in local infection of pancreas, leading to inflamma-
tion, tissue damage, and the release of normally sequestered antigens, which activate poten-
tially self-reactive T cells (Horwitz et al., 1998).
 Alternatively, viral infections may locally induce production of cytokines and other inflamma-
tory mediators in exocrine cells in pancreas that may affect β cells directly by their toxic ef-
fects, a mechanism also called ‘innocent bystander damage’ (Chehadeh et al., 2000;
Rabinovitch, 1992; See & Tilles, 1995).
2.6.1. Cell lysis
Virus variants that have a potential to induce a diabetes-like syndrome in mice have been pri-
marily isolated from patients with rapid onset diabetes (Yoon et al., 1979). Mice infected with
coxsackievirus B4 usually develop acinar pancreati, but not diabetes (Caggana et al., 1993).
CBV4 strains can, however, be adapted to replicate in murine islets and β-cells in vitro (Yoon
et al., 1979). By this method, both Coxsackie B3 virus (Vuorinen et al., 1992; Yoon et al.,
1998) and coxsackie B4 virus (Yoon et al., 1979)  were shown to be able to infect human β-
cells. Coxsackie B viruses are not, however, the only enteroviruses affecting β-cells. Several
strains of enteroviruses have been shown to infect cultured human β-cells and either kill them
or impair their function (Roivainen et al., 2000). Based on studies by Roivainen enteroviruses
can be divided to those directly destroying β-cells by virus-induced cytolysis and to less ag-
gressive viruses, which cause damage of β-cells through inflammatory reactions (Roivainen et
al., 2000). The most recent data indicate that even different isolates of the same serotype can
differ in β-cell destruction (Roivainen 02, in press).
2.6.2. Bystander damage
Horwitz et al. (1998) infected different strains of mice with CBV4-E2 to investigate if mo-
lecular mimicry between GAD65 and CBV4 2C protein or bystander T-cell activation account
for the diabetogenic nature of CBV4-E2. No viral acceleration of diabetes was shown in
NOD-mice, indicating that molecular mimicry between GAD65 and CBV4-2C does not medi-
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ate diabetes. Another mice used in this study was BDC2.5 transgenic mice with diabetogenic
T-cell reseptor specific to an islet cell autoantigen that is different from GAD65 and does not
cross-react with CBV4. These mice do not develop spontaneous diabetes but maintain a large
number of resting islet-specific T-cells. CBV4-E2 infection of BDC2.5 transgenic mice rap-
idly induced diabetes in BDC2.5 transgenic mice through bystander damage of β-cells and
reactivation of the resting autoreactive anti-islet lymphocytes. Another group observed that
infection with CBV4-E2 can accelerate diabetes in NOD through the induction of bystander
activation, but only after a critical threshold level of β-cell-autoreactive T cells have accumu-
lated (Serreze et al., 2000). Based on their studies the authors presume that coxsackievirus
infection might not initiate β-cell autoreactive immunity, but could accelerate an already on-
going process, and timing of coxsackievirus infection in humans could be important factor in
development of autoimmunity to β-cells. Horwitz’s studies further confirmed that β-cell spe-
cific autoreactive T cells within the pancreas are activated due to the release of sequestered
antigen from the damaged tissue and not due to Th1 cytokine induction following viral infec-
tion (Horwitz et al., 2001). Recently, other groups have reported that preproinsulin and proin-
sulin are early targets in T1D and the authors propose that viral infection could release immu-
nogenic prehormones or insulin from β cells, possibly inducing autoreactive T cells (Chen et
al., 2001; Congia et al., 1998).
2.6.3. Molecular mimicry
2.6.3.1. Concept of molecular mimicry
Antigenic molecular mimicry is defined by cross-reactive immunity due to structural or func-
tional homologies between molecules encoded by distinct genes. Several viruses and microbes
have been reported to be associated with autoimmune diseases (Table 2), even though the in-
terpretation is often complicated, since the viral or microbial infection that initiated the au-
toimmune response usually is not present any longe at the time of disease diagnosis. Viral in-
fections may cause loss of self-tolerance by altering the cytokine profile, exposition of seques-
tered proteins,  or by stimulating the production of autoreactive T cells.
One group of proteins associated with autoimmune diseases are HSPs. Immune responses to
microbial HSPs are speculated to initiate chronic inflammatory disease, in which an autoim-
mune response to HSP60 may be central to the pathogenesis (Jones et al., 1990). Both cellular
and humoral antibody responses to autologous HSP60 peptides have been identified in pa-
tients with several chronic inflammatory diseases (Jones et al., 1993). Human HSP60 shares
sequence homology with many autoantigens, including those being target molecules in T1D,
rheumatoid arthritis (RA) and multiple sclerosis, and this homology is thought to be involved
in these autoimmune diseases through molecular mimicry. In each case the target antigen is
specific for the cell type involved and has a region of similarity to human HSP60 (Table 2).
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In diabetes, viral infection may induce expression of HSP60 in the islets. Bacterial HSPs may
initially elict activation of HSP-specific T/B cells, which later react with autologous
HSP via molecular mimicry principle. In healthy individuals, a balanced network of poten-
tially self-reactive B cells and T cells exists. These cells  have evaded clonal deletion in the
thymus, but are usually eliminated by the host immune system or they remain anergic. How-
ever, tolerance to self-antigens may be distorted by encounters of the immune system with for-
eign microbial antigens.
Table 2. Examples of autoimmune diseases with indication of a microbial trigger (modified
from report by Oldstone 1998) and examples of similarity between human HSP60 and
autoantigens (modified from report by Jones 1993).
Disease Cross-reactive immune responses References
Myocardial Cardiac myosin/ Cunninghamet al., 1992
Streptococci, CBV3 Huber et al., 1993
Herpes stomal keratistis Corneal antigen(s) Zhao et al.,1998
Herpes simplex
T1D Islet cell antigens/ Atkinson et al., 1994,
Coxsackieviruses Honeyman et al. 1998
Rotaviruses
Disease HSP60/autoantigen region References
Coxsackie myocarditis HSP60 aa 86-100/ Beisel et al.,1990
Cardiac myosin heavy
chain  aa516-530
T1D HSP aa 391-405/ Baekkeskov et al., 1990
GAD65 aa 520-534
2.6.3.2. Molecular mimicry in T1D
GAD65 has been reported to have cross-reactive determinants with many viruses and also with  β-
cell autoantigens (Jones & Crosby, 1996a;  Kaufman et al., 1992; Rudy et al., 1995; Vreugdenhil et
al., 1998). Most attention has been focused on sequence homology revealed between GAD65 and
the non-structural protein 2C of coxsackieviruses (Atkinson et al., 1994; Tian et al., 1994). This
homologous sequence in GAD65 (PEVKEK) has been shown to be a part of a diabetes-related T-
cell epitope both in NOD-mice and in man (Atkinson et al., 1994; Schloot et al., 1997; Tian et al.,
1994; Vreugdenhil et al., 1998) and  induced cellular and humoral cross-reactive immune re-
sponses with the 2C region (Atkinson et al., 1994; Lönnrot et al., 1996).
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In contrast, Richter et al. did not find cross-reactivity to GAD65 and 2C specific antibodies or
between antibodies to GAD65 and the homologous HSP60 peptide (Richter et al., 1994). T-
cell lines specific to CBV4 2C protein failed to respond to whole GAD65 protein and also to
GAD65 peptides containg the shared PEVKEK sequence (Marttila et al., 2001). Also, accord-
ing to other groups, the importance of this PEVKEK homology in type 1 diabetes was not
proved (Horwitz et al., 1998; Lohman et al., 1994; Schloot et al., 1997; Vreugdenhil et al.,
2000).
It has also been shown that epitope in proinsulin residues 24-36 and GAD65 residues 506-518
have sequence homology (Rudy et al., 1995), which could induce cross-reactive immune re-
sponses in an early autoimmune event of T1D (Chen et al., 2001).
Diabetes-associated T-cell epitopes in IA-2 have been characterized (Hawkes et al., 2000;
Honeyman et al., 1998; Peakman et al., 1999) and sequence comparison revealed similarities 
of these epitopes with various viruses and dietary proteins (Honeyman et al., 1998). The pre-
dominant IA-2 epitope (amino acids 805-820) was found to have 56 % identity and 100 %
similarity over nine amino acids with a sequence in VP7, a major immunogenic protein of hu-
man rotavirus. This epitope also has sequence homology to Dengue virus, CMV, measles vi-
rus, hepatitis C virus and with autoantigen GAD65. Further, other epitopes in IA-2 had se-
quence similarity with some viruses and dietary proteins of milk and wheat (Honeyman et al.,
1998). Later it was shown that there was a specific and highly significant association between
rotavirus seroconversion and increase in antibodies to IA-2, insulin and GAD65 suggesting
that RV infection may trigger or exagerate islet-cell autoimmunity in genetically susceptible
children (Honeyman et al., 2000).
In addition to GAD65 and IA-2, other homologous molecules have been detected between  β-
cell autoantigens and environmental agents associated with T1D (Table 3).
Table 3. Examples of identified homologies between β-cell autoantigens and environmental
agents associated with T1D
β-cell autoantigen Sequence homology References
GAD65 Coxsackievirus 2C-protein, Kaufman et al., 1992
rotavirus, HSP60, proinsulin Jones et al., 1996
ICA69 Bovine serum albumin, ββ casein Karges et al., 1995
Karjalainen et al., 1992
IA-2 Rotavirus, Denguevirus Honeyman et al., 1998
Dietary proteins, GAD65
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3. AIMS OF THE PRESENT STUDY
By sequence comparison we found homologies between enterovirus capsid/procapsid protein
VP1/VP0 and diabetes-associated epitopes in β-cell autoantigens IA-2/IA-2β and HSP60. The
purpose of the study was to clarify if this sequence homology can induce cross-reactive im-
mune responses (molecular mimicry) to enteroviruses and islet cell autoantigens, one possible
mechanism by which enteroviruses could induce  β-cell destruction. The specific aims were:
1. To study immunological cross-reactions between antisera raised against enterovirus pro-
teins, islet cell proteins and peptides derived from homologous regions of these proteins.
2. To investigate if immunization with enteroviruses in rabbits and in NOD-mice induces
cross-reacting immune responses.
3. To study if enterovirus infection in humans induces immune responses that cross-react with
β-cell autoantigens.
29
4.  METHODS AND SUBJECTS
4.1. Antigens
Viruses, proteins, peptides and corresponding antisera used in this study are described in Table 4.
4.1.1. Viruses
Virus strains used in this work were prototype strains obtained originally from the American
Type Culture Collection (ATCC) or the World Health Organization (WHO), Reference Labo-
ratory of Enteroviruses. African green monkey kidney cells (GMK) were used for propagation
of coxsackievirus B4/J.V.B (CBV4), coxsackievirus B5/Faulkner (CBV5) and coxsackievirus
A9/Griggs. A-549, a human lung carcinoma cell-line, was used for propagation of human
parechovirus 1/Harris (HPE-1). Poliovirus type 3/Sabin (PV3) was grown in WHO-Hep2c
cells. A diabetogenic strain of coxsackievirus B4 (CBV4-E2) was kindly provided by Dr. Yoon
(University of Alberta, Canada). Crude virus preparations were cleared from cell debris by
low-speed centrifugation and used as such or further purified in 5-20 % sucrose gradient
(Abraham & Colonno, 1984).
4.1.2. Peptides
Peptides used in this work were synthetized and purified by high performance liquid chroma-
tography at Department of Biochemistry, University of Helsinki or Department of Biochemis-
try, University of Turku, Finland. Peptides were derived from the conservative region of
coxsackievirus B and poliovirus type 3 capsid protein VP1 (pVP1a, and pVP1b, pVP1c, re-
spectively), procapsid protein pVP0, two overlapping peptides from C-terminal part or IA-2/
IA-2β (pIA-2a, pIA-2b) and immunogenic region of HSP60 (pHSP60) (Table 4).
4.1.3. Proteins
Fusion proteins GST-VP0, GST-2C, His-VP0, His-VP1 were expressed and purified by us
(see below). Recombinant HSP60, Mycobacterium bovis, was a gift from Dr. M. Singh, GBF,
Braunschweig, Germany. Recombinant human HSP60 was from Stress Gen, Victoria, Canada.
Chlamydia pneumoniae HSP60 was produced at the Vaccine Development Laboratory, Na-
tional Public Health Institute, Helsinki, Finland. The intracellular region of human tyrosine
phosphatase (ICD-IAR) was kindly provided by Dr. C. Pallen (National University of
Singapore).
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4.2. Expression and purification of virus proteins
4.2.1. GST-VP0 and GST-2C (I)
Sequences coding for CBV4 VP0 and 2C were amplified by polymerase chain reaction using
CBV4 cDNA (a gift from Dr. J.Almond, University of Warwick, UK) using primers with
BamHI restriction sites at ends. PCR products were digested with restriction enzyme and
cloned into pGEX-2T expression vector (Pharmacia P-L Biochemicals Inc.) for protein ex-
pression. BglII adapter shifting the frame by two nucleotides was used to get the 2C protein in
frame with GST fusion protein.
pGEX-2T-VP0, pGEX-2T2+-2C and pGEX-2T plasmids were transformed into E.coli BL-21
cells and expression of proteins was induced by IPTG. The cells were harvested by centrifuga-
tion and lysed with a French press and centrifuged to separate cell debris and supernatant. Fu-
sion proteins were purified both in denatured form from insoluble fraction and in native form
from supernatant. Insoluble fusion proteins in pellets were extracted with detergents and
exised from SDS-PAGE gel. Purification of soluble fusion proteins and GST from supernatant
was carried out by GST-sepharose columns basically according to manufacturis instructions
(GST Gene Fusion System, Pharmacia Biotech Inc).
4.2.2. His-VP0 and His-VP1 (II)
Coxsackievirus A9 (CAV9) and coxsackievirus B4 (CBV4) cDNAs (kindly provided by Dr. G.
Stanway, University of Essex, UK and Dr. J. Almond, University of Warwick, UK) were used
as templates to amplify VP0 of CBV4 and VP1 of CAV9 by PCR. The amplified product of
VP0 was cloned to BamHI site, VP1 to BamHI-EcoRI site of histidine tagged expression vec-
tor pPROEX-HTb (Gibco BRL, Gaithersburg, MD, USA). Transformed E.coli BL-21 cells
were induced with IPTG, harvested after a few hours and the cells disrupted with a French
press. Fusion proteins were finally extracted from pellet in soluble form with 8 M Urea, 100
mM NaCl, 20 mM Tris-HCL (pH 8.0) and purified by Ni-NTA agarose (Qiagen, Chatsworth,
CA, USA) under denaturing conditions.
4.3. Antisera
For production of antisera three sequential doses of purified virus, peptide or recombinant
protein were injected into rabbits in Freund’s complete (FCA) or  incomplete (FIA) adjuvant
(Table 4). The insoluble pellets of GST-VP0 and GST-2C were run on a SDS-PAGE, exiced,
homogenized and used in immunization. For production of His-VP0 and His-VP1 antisera,
Ni-NTA purified proteins were run on SDS-PAGE and protein bands exiced from gel.
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Two polyclonal antisera to Mycobacterium bovis HSP65 (rabbit number 13 and 19) were a gift
from Dr. Q. Xu and Prof. G. Wick (Austria Academy of Science, Innsbruck, Austria).
4.4. Immunological methods
4.4.1. Enzyme immune assay (EIA) (II, III, IV, V)
High binding microtiter wells were coated with peptides, expression proteins or purified virus
particles in 50 mM NaHCO3, pH 9.4. The plates were washed three times with PBS-Tween
20 (0.1%) and the wells blocked with PBS-BSA (0.1%) or PBS-casein (0.1%) for 30 min at
RT. The wells were washed as above and incubated with test sera, diluted in the EIA buffer
(PBS, 1% BSA, 0.1% Tween 20, 5 mM EDTA, 1% FCS), for 2 hours at 37 °C. The wells were
washed and the reaction visualized by species specific conjugates. For blocking experiments
antisera were preincubated with antigens before addition to wells.
4.4.2. Immunoblotting (I, II)
Proteins and viruses were separated by SDS-PAGE and transferred electrically to nitrocellu-
lose membranes. Nonspecific binding was prevented with PBS-5% milk and membranes incu-
bated with specific antisera diluted either to PBS-5% milk powder or 20 mM TBS, pH 7.4
containing 2% BSA. Detection of binding was achieved with HRP-conjugated anti-rabbit se-
rum. Blocking experiments were done by preincubation of sera with antigens before addition
to the membranes. Peptides were immobilized as spots on membranes and assays performed
as describes above.
4.4.3. Immunoprecipitation (I)
GMK cells were infected with CBV4 and grown in methione-free medium for 4 h before addi-
tion of 35 S-methione and the labelled virus was immunoprecipitated as described in earlier
(Roivainen et al., 1993b)
4.4.4. Epitope mapping (III, IV)
Partially overlapping peptides of capsid proteins VP1-VP4 of CAV9, nonstructural 2C protein
of CBV4 and β-cell autoantigens IA-2, preproinsulin, GAD65 and HSP60 were synthetized
on cellulose membranes in 384-spot format (SPOTs, Genosys, Inc) with a 12 amino acid win-
dow and three residue shift. The membranes were blocked with casein based blocking buffer
(Genosys) or 5% dried milk, 5% sucrose and TBS-Tween20 (0.05%) pH 8.0) overnight at +4
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°C and incubated with serum dilutions, either virus induced rabbit, NOD mouse or human
sera. After washings with TBS-Tween20 (0.05%), the membranes were incubated with the
HRP-conjugated antiserum, washed and finally covered with thin layer of ECL reagent
(Amersham and NEN Life Science Products). The chemiluminiscence of spots was deter-
mined with a scintillation counter (Perkin Elmer Life Science, Wallac, Turku) and verified by
autoradiography.
4.5. Plaque neutralization
Sera obtained from diabetic children were assayed for the presence of neutralizing antibodies
to CAV9 and CBV4 as described earlier (Roivainen et al., 1998).
4.6. Immunization of non obese diabetic (NOD) mice
F1-generation of NOD/-Bom mice, obtained from M&B A/S, Copenhagen, Denmark, were
raised and maintained under pathogen-free conditions. Female offsprings were immunized
intraperitoneally with inactivated CBV4-E2 or with PBS in Freund’s incomplete adjuvant. The
amount of virus used and immunization protocol differed in different groups and are shown in
original publications III and IV. Onset of diabetes was monitored by measuring blood glucose
consentration (>13 mmol/l hyperglycemic)
4.7. T-cell proliferation assay (IV)
Spleen cells from NOD-mice were incubated in triplicate with different antigens in RPMI-
1640 supplemented with 25 mM Hepes pH 7.4, 50 µM β-mercaptoethanol, 5% FCS and 25
µg/ml gentamycin. After 48 hours stimulation tritiated thymidine (1 µ Ci/ml) was added and
cells harvested 18 hours later for counting tritium incorporation with Victor (Perkin Elmer
Life Science, Wallac, Turku)
4.8. Cytokine assay (IV)
Single cell suspensions of spleens were incubated with test antigens in culture medium and
tested for presence of cytokines using commercial EIA assays (IL-2, 19211T; IFN-γ, 19301T;
IL-4, 19231V; IL-10, 19281V; Pharmigen, San Diego, USA).
4.9. Adoptive transfer of diabetogenic splenocytes (IV)
Spleen cells of clinically diabetic mice were collected and mixed with an equal number of
splenocytes isolated from 14 weeks old healthy NOD-mice immunized either with CBV4-E2
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or PBS. T-lymphocyte mixtures (20 x 106), were transferred intravenously to female NOD-
scid mice at 5 weeks of age. The development of diabetes was tested weekly by measuring
glucose concentrations from urine (1-4 weeks) or blood (5-10 weeks). Recipients remaining
normoglycemic were scored negative for adoptive transfer.
4.10. Human subjects (III and V)
Detailed data of human subjects and study groups are given in original papers (III and IV) and
are only summarized here.
110 paired sera, collected during documented enterovirus infections, were obtained from the
Netherlands, Sweden, and Finland (III, IV, V).
In report IV, blood samples were obtained from 73 Finnish children vaccinated according to
the standard vaccination protocol (Piirainen et al., 1999) with the Salk type of IPV given at
the age of 4 and 7 months and OPV at 18 months old.
In report IV, sera were obtained from 20 children with diagnosed type 1 diabetes, previously
tested for presence of antibodies to insulin (IAA), IA-2 (IA-2A) and GAD65 (GADA). A
blood sample was also obtained from eight healthy children.
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Table 4.  Peptides, proteins, viruses and the corresponding antisera.
antigen code sequence adjuvant antisera codes
Coxsackie- p41/pVP1a EAIPALTAVETGHTSQVC FCA 482, 522,552, 392, 1331, 1231
derived VP1
poliovirus - pB99-5/pVP1b KEVPALTAVETGATC FCA/OVA 900, 910, 920, 642,
P3/VP1 FIA 6337
poliovirus/P3      p37/pVP1c KEVPALTAVETGATNPLVC FCA 1051, 112, 582, 602,
Sabin/VP1
CBV4/VP0 p125/pVP0 VMIKSPALNSPTVEEC FCA 154, 164, 983
IA-2/IA-2β p331/ KEQFEFALTAVAEEVC FCA 4033, 4013
pIA-2 FIA 4600
IA-2/IA-2β p332/ EFALTAVAEEVNAILKALC FCA 4183, 4091
pIA-2 FIA 4556
HSP60/ p124/pHSP60 ALLRCIPALDSLTPANEDC FCA 124, 134
human
Proteins code expression and purification adjuvant antisera code
CBV4/VP0 GST-VP0 E.coli, SDS-gel extraction FIA/denatured N25, N125
GST-VP0 E.coli affinity-purified FIA/native N48, N60
CBV4/2C GST-2C E.coli SDS-gel extraction FIA/denatured N85, N95
GST GST E.coli affinity-purified FIA/native N115
CBV4/VP0 His-VP0 E.coli SDS-gel extraction FIA/denatured k3898
CAV9/VP1 His-VP1 E.coli SDS-gel extraction FIA/denatured k3944
Mycobacterium HSP65/Myco E.coli affinity purified 13, 19
bovis HSP65
Chlamydia HSP60/Cpn Bacillus  in denaturated form FCA/FIA 1504, 1505
pneumoniae HSP60
virus code propagation adjuvant antisera code
coxsackievirus B4/J.V.B CBV4 GMK FIA 265, 275
coxsackievirus A9/Griggs CAV9 GMK FCA 861, 3896
coxsackievirus A9/Griggs CAV9 GMK FIA 4952
coxsackievirus B5/Faulkner CBV5 GMK - -
poliovirus type 3/Sabin polio, PV3 WHO-Hep2c FCA 808
human parechovirus 1/Harris HPE-1 A-549 FCA 3912
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5. RESULTS AND DISCUSSION
One mechanism by which enteroviruses could induce or accelerate β-cell destruction, eventu-
ally resulting in clinical type 1 diabetes is through immunological cross-reactivity of enterovi-
rus proteins and islet cell autoantigens. This ‘molecular mimicry’ principle is largely based on
sequence similarity between diabetes associated region of glutamic acid decarboxylase
(GAD65) and the nonstructural 2C protein of enteroviruses (Atkinson et al., 1994; Hovi,
1998; Kaufman et al., 1992b).
By sequence comparison (II, III) we found additional homologies between enteroviruses and
diabetogenic epitopes in islet cell autoantigens IA-2 (Honeyman  et al., 1998), and in HSP60
(Elias & Cohen, 1994; Elias et al., 1991; Raz et al., 2001) (Table 5). An immunogenic diabe-
tes associated HSP peptide (p277) had sequence similarity with VP0 of enterovirus capsid
protein and with conservative region of the VP1 protein (Table 4, 5). It has been indicated that
this peptide p277 (amino acids 437-460) in HSP60 is an important autoantigen in NOD-mice:
autoreactive T-cells are directed to it, and when attenuated in vitro, these T-cells can protect
from diabetes (Elias et al., 1990). This peptide has been used as therapeutic agent both in
NOD-mice and recently also in humans (Abulafia-Lapid et al., 1999; Elias et al., 1991). An
immunogenic, conservative epitope of VP1 PALTAVET G/AT had also sequence homology
with a region in the C terminal end of IA-2 (ALTAV), which has been shown to be part of dia-
betogenic T-cell epitope (Honeyman et al., 1998; Peakman et al., 1999). A high percent of pa-
tients with type 1 diabetes also have antibodies directed against the C terminal end of IA-2
(Leslie et al., 1999).
 These observations prompted us to investigate immune responses induced in animals and hu-
mans by these proteins and homologous peptides derived from them using various immuno-
logical assays. As cross-reactive epitopes can be differently exposed in different tests, antise-
rum was considered cross-reactive if it gave positive results by either EIA or immunoblotting,
or both.
Table 5.  Sequence comparison of CAV9 VP1 and VP0 regions with HSP60 (a).  Sequence
comparison of pIA-2a (tyrosine phosphatase) and pVP1a (coxsackievirus-  derived) peptides
(b). Identical amino acids are shown in bold.
a
CAV9 VP0 VMIKSLPALNSPTVEECG
HSP60 ALLRCIPALDSLTPANED
CAV9 VP1 SNSASVPALTAVETGHTS
b
pVP1a -EAIP-ALTAVETGHTSQVC
pIA-2 KEQFEFALTAVAEEVC
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5.1.  Preparation and characterization of tools (I, II)
5.1.1.  Expression of viral proteins in E.coli and production of antisera
Coxsackievirus B4 (CBV4) capsid protein VP0 and nonstructural 2C proteins were expressed
as GST-fusion proteins in E.coli using CBV4 cDNA as template and expression vector pGEX-
2T. Initially used induction conditions (37 °C, 0.5 mM IPTG) gave high expression levels, but
insoluble fusion proteins. The solubility of proteins was significantly increased by lowering
temperature (RT) and inducer concentration (0.05mM), that allowed the purification of  both
fusion proteins, GST-VP0 and GST-2C by glutathione sepharose column in a soluble form.
Attempts to cleave off the GST-part by thrombin resulted in degradation of the viral part of
fusion proteins and therefore the fusion proteins as such were used in rabbit immunizations
(Table 4). Rabbits were also immunized with denatured fusion proteins, obtained by extrac-
tion from insoluble pellet fraction with detergents (Triton X-100, Tween-20 and SDS), which
solubilized most of the bacterial proteins, but not the fusion proteins, which were then excised
from SDS gels for immunization.
Fusion protein specific antisera recognized the corresponding recombinant protein in a dilu-
tion of  1:50 000. Reactivity was observed between fusion proteins and GST, only with
weaker intensity. Antisera raised against denaturated and native GST-VP0 recognized VP0 and
the cleavage products of VP0, VP2 and VP4 of CBV4 in immunoblotting at 1:20 000 dilution.
Immunoblotting also revealed antigenic cross-reactivity with other enteroviruses CAV9 and
CBV5, which is consistent with previous results showing high degree of cross-reactivity be-
tween enteroviruses (Hohenadl et al., 1994). That reacting antibodies are directed to the viral
domain of fusion protein was confirmed by preincubation of GST-VP0 antiserum with GST,
which abolished the reaction with GST but not with virus.
As purified virus preparations do not contain nonstructural 2C, CBV4 infected GMK cell ly-
sates were used to verify 2C reaction by immunoprecipitation. Antisera raised against dena-
tured GST-2C fusion protein precipitated a protein corresponding to molecular size of 2C.
The purity of fusion protein preparations was confirmed by immunoblotting with VP0-pepide,
MBP-2C (from Dr. L. Carrasco), GST-VP0, GST-2C and GST induced antisera. In addition to
full size expression proteins, immunoblotting confirmed that smaller molecular weight by-
products in the preparations were of fusion protein origin, not impurities from E.coli. These
fusion protein preparations have been successfully used in lymphocyte stimulation experi-
ments in determination of T-cell epitopes of enteroviruses and in the characterization of prolif-
erative responses in diabetes patients and and healthy subjects (Juhela et al., 2000; Marttila et
al., 2002; Marttila et al., 2001).
Attempts to express CAV9 as soluble GST-fusion protein were unsuccessful. We later
 expressed VP1 and VP3 of CAV9 and VP0 of CBV4 in His-tagged form (His-VP1, His-
VP3, His-VP0), but this did not overcome the solubility problem for any of these proteins.
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However, the proteins could be purified to high degree by Ni-NTA agarose under denaturing
conditions. To avoid urea in eluates in rabbit immunization these fusion proteins were excised
from SDS gels. Polyclonal antisera raised against His-fusion proteins recognized the corre-
sponding immunogen and purified virus protein in immunoblotting, and both antisera and fu-
sion protein preparations were used in studies II and IV.
5.1.2. Peptides and peptide induced rabbit antisera (1, II, III, IV)
Peptides corresponding to immunogenic regions of VP1 (coxsackivirus- and poliovirus de-
rived pVP1, and pVP1b, pVP1c, respectively), HSP60 (pHSP) and IA-2/ (pIA-2a) and a
longer partially overlapping pIA-2b (Table 4) were used in EIA and immunoblotting either as
free molecules or coupled to BSA and used in rabbit immunizations (Table 4). The sera recog-
nized the corresponding peptide in EIA and preimmune were negative. Because sera from par-
allel immunizations with these peptides behaved highly similarly not all reactions are shown in
this section or in original manuscripts (I, II, III, IV, V).
5.2. Islet cell autoantigens, HSP60 (II) and IAR-2 (III) share antigenic epitopes with en-
terovirus capsid proteins
5.2.1. Cross-reactions detected with viral and tyrosine phosphatase derived peptides
Possible cross- reactivities were tested by EIA and/or immunoblotting. Antisera raised against
immunogenic epitope of tyrosine phosphatase IA-2/IA-2β (pIA-2a) (KEQFEFALTAVAEEVC)
recognized coxsackievirus derived VP1 and VP0 peptides EAIPALTAVETGHTSQVC and
VMIKSPALNSPTVEEC (pVP1a and pVP0, respectively). All of the pVP1a (coxsackievirus
derived) induced antisera tested cross-reacted with pIA-2a, while none of nine poliovirus de-
rived KEVPALTAVETGATC  and  KEVPALTAVETGATNPLVC (pVP1b and pVP1c, respec-
tively) induced antisera recognized this peptide. The result is somewhat unexpected, as the
sequences in polio-and coxsackieviruses are very similar. Indeed, when used as an antigen in
EIA, poliovirus derived peptide was recognized by IA-2a-peptide-induced antisera. Similarly,
both poliovirus peptide induced antisera recognized coxsackievirus pVP1a peptide as well
purified CAV9 and CBV4 in EIA (not shown). Possibly amino acid(s) outside the homologous
motif influence the reactivity of antibodies produced. On the other hand,  pVP1b and pVP1c
peptides may have formed conformations in which the homologous region is not exposed for
recognition in rabbits. Similar discordance with antibody responses was observed with two
tyrosine phosphatase peptides, pIA-2a and a partly overlapping, longer peptide of the same
region in tyrosine phosphatase pIA-2b EFALTAVAEEVNAILKALC. While pIA-2a induced
antisera recognized both the corresponding immunogen (pIA-2a), the longer peptide pIA-2b
and both viral peptides, antisera raised against the longer tyrosine phosphatase peptide pIA-2b
basically recognized only the corresponding peptide.
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The specificity of the reactions between tyrosine phosphatase peptide pIA-2a and viral pep-
tides was tested with blocking experiments. Preincubation of pIA-2a induced antiserum with
the corresponding immunogen or with pVP1a abolished the recognition of VP1 peptide. The
reaction of the same antiserum with pVP0 could only be blocked by preincubation with corre-
sponding peptide (pIA-2a). Recognition of IA-2a peptide by the two viral peptide-induced an-
tisera could be blocked both with corresponding viral peptide and with pIA-2a. No cross-reac-
tivity was observed between viral VP1 and VP0 peptides.
The summary of cross-reactive immune responses by EIA is presented in Table 6. As a whole,
parallel peptide induced antisera gave similar results, and not all results are shown in original
manuscript (III). All of the tested rabbit preimmune sera were negative.
Table 6. Cross-reactive immune responses observed between PTP-like peptides (pIA-2a and
pIA-2b), coxsackievirus derived (pVP1a), poliovirus derived (pVP1b, pVP1c) and CBV de-
rived VP0 peptides. The data shows positive reaction/tested antisera. NT, not tested.
antiserum 1:50
αpIA-2/ αIA-2 / αpVP1 αpVP1 αpVP1 pVP0
peptide IA-2a IA-2b (a) (b) (c)
pIA-2a 3/3 1/3 4/4 0/6 0/3 1/3
pIA-2b 3/3 3/3 0/4 NT 0/3 0/3
pVP1a 3/3 0/3 4/4 6/6 3/3 0/3
pVP1b 0/3 0/3 4/4 6/6 3/3 0/3
pVP1c NT NT NT NT NT NT
pVP0 3/3 0/3 0/4 0/6 0/3 3/3
5.2.2. Cross-reactivity observed with proteins
Characterization of possible immunological cross-reactions between enterovirus proteins and
islet cell antigens were further studied using viral expression proteins, human HSP60, HSP65/
M.bovis, HSP60/Cpn, intracellular part of IAR and purified virus preparations.
5.2.2.1. Immune responses induced by enteroviruses and heat shock proteins (HSPs) (II)
The current study was prompted by the discovery of a moderate degree of homology beteen
enterovirus capsid proteins and an immunogenic, diabetes-associated epitope in human
HSP60 and HSP65 of M. bovis, an epitope named p277 in literature (Elias et al., 1990, 1991).
Heat-shock proteins are phylogenetically highly conserved proteins, still microbial HSPs are
known to be highly immunogenic in humans and induce immune responses in many bacterial
and parasitic infections (Young, 1990). Furthermore, numerous different regions of human
HSP60 have been shown to possess sequence similarity with many autoantigens (Jones et al.,
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1993) (Table 2) and they have been associated with a series autoimmune diseases, e.g type 1
diabetes (Abulafia-Lapid et al., 1999; Elias et al., 1991; Horvath et al., 2002).
In order to evaluate whether enteroviruses share antigenic determinants with HSP60/65, two
polyclonal antisera raised to Mycobacterium bovis HSP65 (HSP65/Myco) (Table 4) were
tested for reactivity with CBV4 and CAV9 in immoblot and in EIA. Both of these were shown
to cross-react with Chlamydia pneumoniae (HSP60/Cpn), and one of the two, which strongly
reacted with human HSP, also recognized purified CAV9 (VP1) and CBV4 (either VP1or VP0
proteins). Both of the two antisera raised against HSP60/Cpn also recognized human HSP60
and mycobacterial HSP65, and one of two antisera also recognized purified CAV9 and the re-
combinant VP1 protein of CAV9 in EIA. In immunoblotting both antisera did, however give
positive reaction with purified viruses (CAV9, CBV4). The authenticity of virus recognition
was confirmed with blocking experiments using corresponding HSP immunogens and virus
preparations. CBV4 capsid proteins VP1 and VP2 are not separated in SDS-PAGE, but the
results obtained with recombinant VP1 and VP0 proteins and in blocking experiments with
purified VP1 indicated that the reacting protein is VP1, not VP2.
Cross-reactive immune responses were less clear the other way around. Antisera raised against
purified enteroviruses and recombinant viral proteins did not cross-react with human HSP60,
while some reactivity was seen against bacterial HSPs. Among  numerous virus antisera
screened, antiserum to human parechovirus 1 (HPE-1), a virus formerly classified to enterovi-
ruses, reacted with human HSP60 but not with bacterial HSPs. The motif inducing this cross-
reaction remains unclear, as the homologous region in VP1 does not exist in HPE-1. Some
cross-reactivity was seen to VP1a and HSP peptides in immunoblotting, but compared to IA-
2a peptides this was not so clear.
In the present study, immunological cross-reactivity was shown in antisera raised  HSPs and
VP1 protein of coxsackie viruses. The importance of immune response to HSP60 and espe-
cially to its p277 peptide has been clearly demonstrated in NOD-mice (Elias & Cohen, 1994;
Elias et al., 1990, 1991). In NOD-mice antibodies against HSP60 occured spontaneously be-
fore the onset of clinical disease, declining at the time point of manifested clinical diabetes
(Elias et al., 1990). Recently, by epitope mapping antibodies specific for p277, present both to
in human HSP60 and M.Bovis, were shown to be significantly higher in diabetic patients com-
pared to healthy children (Horvarth et al., 2002). No significant difference was, however,
found in the antibody levels to whole HSP proteins. The signicance of these epitope-specific
antibodies in the pathogenesis T1D is unclear. They may indicate that these antibodies have a
role in the autoimmune process against β-cells or they could be a secondary phenomenon re-
sulting from cell damage.
Our results indicate that immunological cross-reactivity exist between HSPs and enterovirus
VP1 protein, which can be induced by peptides carrying a homologous motif between the pro-
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teins. However, our results do not exclude the possibily that there are other motifs as well. For
example conformational structures are capable of inducing the observed cross-reactions.
5.2.2.2. Immune responses induced by enteroviruses and tyrosine phosphatase
 IA-2/IA-2β (III, IV)
The results obtained with virus and IA-2 peptide-induced rabbit antisera clearly showed that
immunizations with these peptides are able to induce cross-reacting antibody responses. The
cross-reactivity was not, however, limited to peptides. When purified viruses were used as an
antigen in EIA, antisera raised against IA-2a peptide recognized purified CAV9, CBV4-E2
and CBV5 with no obvious difference in recognition in used assay conditions.
On the contrary, when antisera raised against purified virus were tested for reactivity, a phe-
nomenon similar to that previously observed with peptide antisera reoccured. Both of CBV4,
and one of three CAV9 induced rabbit antisera reacted with IA-2a peptide, but the poliovirus
antiserum did not react with the pIA-2a peptide. The intracellular part of IAR was recognized
by both VP1a and IA-2a induced antisera, while antisera against VP0 peptide did not recog-
nize the protein.
Epitope mapping data further confirmed the results obtained by EIA. Synthetic peptides com-
prising IA-2 protein from 7-979, immobilized on membrane, were incubated with peptide-
and CBV4- induced antisera. Antiserum raised against IA-2a-peptide recognized four peptide
spots corresponding to peptide sequence aa 955-975 in IA-2
(SKDQFEFALTAVAEEVNAILK), three of the peptide spots containing the ALTAV sequence.
The pVP1a induced antiserum, used at a dilution as high as 1:70 000, recognized these three
peptides, all containing the whole ALTAV sequence. Likewise, the antiserum to purified
CBV4, at dilution of 1:50 000, gave a definite reaction with all ALTAV- motif containing pep-
tide spots. In addition, this serum reacted also with other peptides in the protein, one very
strong reaction was seen in the extracellular part of the protein and one in the intracellular
part, earlier shown be be diabetes associated T-cell epitope (Honeyman  et al., 1998; Peakman
et al., 1999). In concordance with the EIA results, antiserum raised against poliovirus derived
peptide (pVP1b) did not react with the ALTAV-motif in IA-2. At a dilution of 1:10 000, two
other regions in IA-2 was recognized, both of which have been shown to activate T-cell prolif-
eration in diabetic patients (Honeyman  et al., 1998;  Peakman et al., 1999).
Epitope mapping with CBV4 induced antiserum gave a definite reaction with three ALTAV
containing peptides in the C-terminal end of IA-2. This part of IA-2, showing amino acid
similarity of 10 amino acid with CBV4 VP1 protein, has been shown by many groups to be
the major antigenic site to which autoantibodies in IA-2 positive diabetic patients are directed.
Besides being a B cell epitope, this ALTAV containing seguence has been identified also as
diabetogenic T-cell epitope (Honeyman et al., 1998; Peakman et al., 1999). Interestingly, the
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cross-reactive amino terminal region of VP1 (21-35) contains a T cell epitope, and immune
responses to this region has been suggested to be important in the pathogenesis of CBV3-in-
duced myocarditis (Huber et al., 1993). In addition to the ALTAV sequence, CBV4-induced
antiserum gave strong reactions also with other parts of IA-2, some of which are also part of
identified diabetogenic epitope (Figure 2). The significance of these immunological cross-
reactions between motifs in IA-2 and virus remains unknown.
5.3. Characterization of viral protein induced epitopes in NOD-mice (IV)
The NOD-mice is widely used animal for characterizing effects of different proteins in devel-
opment of diabetes. It has been shown that autoimmune process against islet cells can be
modulated by administration of different β-cell specific autoantigens to NOD-mice (Elias et
al., 1991; Zhang et al., 1991; Tisch et al., 1993; Trembleau et al. 2000). We were interested in
finding out the immune response induced in NOD-mice by CBV4 immunzation and the effect
of this in the development of diabetes in NOD-mice. Female NOD-mice were immunized
with purified inactivated CBV4-E2, and the individual sera tested for antibodies to CBV4-E2
virus, His-tagged fusion proteins VP0, VP1 and VP3, GAD65, insulin, and peptides corre-
sponding to observed homology motifs in VP1, VP0, IA-2 and HSP60. All immunized mice
had antibodies to purified CBV4 -E2 in EIA. Recombinant His-tagged VP1 protein (His-VP1)
was also recognized by most immunized sera, while more variation was seen with individual
sera in reactivity to recombinant proteins His-VP0 and His-VP3. In capsid proteins VP1 and
VP0 special interest was in the two regions previously shown to cross-react with two islet cell
autoantigens, IA-2 and HSP60 (II, III). The highly immunogenic N terminal VP1 region
(PALTAVETGHT) was recognized by sera from all immunized NOD-mice, while there was
poor reaction towards VP0-peptide. In contrast, many of the immunized NOD-mice had anti-
bodies to pIA-2, confirming our earlier results of cross-reactivity obtained with peptides and
virus-immunized rabbit antisera (III).
Virus-induced humoral responses in NOD-mice were further characterized by epitope map-
ping with partially overlapping peptides in CAV9 capsid proteins VP1-VP4, and islet cell
autoantigens IA-2, insuli, GAD54 and HSP60 (Fig. 2). CBV4-E2 immunization in NOD-mice 
resulted in recognition of epitopes covering the whole capsid, the most intensive reaction di-
rected to VP1, VP3 and VP4 proteins. Recognition of both pVP0 and pVP1 sequences (Table
4) was prominent. Control mice did not respond to viral peptides.
Spontaneous humoral responses in NOD-mice have been observed to GAD65, IA-2, HSPs
and to insulin (Elias & Cohen, 1994; Myers et al., 1998; Tisch et al., 1993) although the re-
sults are somewhat controversial (Bonifacio et al., 2001; DeSilva et al., 1996). The data pre-
sented by the International Workshop on the standardization of autoantibody assays in animal
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models, however, gives strong evidence that insulin antibodies are markers of autoimmunity
in NOD-mice (Bonifacio et al., 2001). In our experiments, insulin autoantibodies predomi-
nated in control NOD-mice at age of 12-15 weeks, while limited reactivity was seen to HSP
and to IA-2 peptides. CBV4 immunization resulted in increased antibody responses to
GAD65, insulin and IA-2 peptides in EIA.
Virus immunization induced humoral responses to islet cells were further characterized by
epitope mapping (Fig. 2). ALTAV and PALLDSPANED (p277) motifs in IA-2 and HSP60,
respectively, were both recognized by CBV4-E2 immunized NOD-mice. In addition, some
other sequences in these proteins were recognized. The virus induced immune response to
preproinsulin was targeted to one epitope located at C-terminal half of the leader peptide,
 aa 10-26 in protein (LLALWGPDPPAAAFVN). This region was recognized to some extent
also by unimmunized control mice suggesting that this motif is a natural humoral epitope in
NOD-mice. The spontaneous recognition of this preproinsulin peptide and a strong immune
response induced against it in virus immunization is intriguing, since this epitope is present
only in immature insulin and the same peptide sequence has been shown to be one of the natu-
rally processed, DRB1*0401-restricted T-cell epitopes in preproinsulin (Congia et al., 1998).
The significance and mechanism of this CBV4-E2 immunization induced PP1 peptide recog-
nition remain to be studied.
In general, CBV4-E2 enhanced B-cell immune responses to certain islet cell epitopes.
Whether this is due to cross-reactive immune responses induced by immunogenic virus pro-
teins and islet cell autoantigens or immunization induced shift from TH1 to TH2 reactivity
with concomitant antibody production, is not resolved.
5.4. Development of diabetes in CBV4-E2 immunized NOD-mice (IV)
Coxsackievirus (CBV4-E2) immunization protected NOD-mice from spontaneous diabetes
and the effect was, at least partially, due to activation of splenocytes by the virus, as shown by
splenocyte transfer. According to our results, concomitant transfer of splenocytes from CBV4-
E2 immunized mice together with lymphocytes obtained from diabetic mice partly protected
NOD-scid mice from diabetes.
CBV4 immunization resulted in strong humoral response to purified virus preparation, many
CBV peptides and to several islet cell autoantigens. On the contrary, only few immunized
mice showed T-cell proliferation in response to virus immunization, but IFN-γ and IL-10 se-
cretion was often detected in response to inactivated CBV4. In NOD-mice, high cytokine re-
sponse to autoantigen without T-cell proliferation has been observed also by other groups
(Trembleau et al., 2000). In our study, T-cell reactivity upon autoantigen stimulation was low
in control NOD-mice, and the responses did not change remarkably in immunized mice.
Female NOD-mice develop diabetes spontaneously and, in contrast to human studies, patho-
gen and islet cell antigen immunizations have been shown to prevent or delay diabetes in
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NOD-mice (Cooke et al., 2001; Cooke et al., 1999; Elias et al., 1995; Kaufman et al., 1993).
Developmental and functional defects have been reported in antigen presenting cells (APC) of
NOD-mice and these defects appear to perturb the presentation of self antigens in the course
of tolerance induction (Lund & Strid, 2000). Some of these defects are associated with defec-
tive secretion of endogenous cytokines. It is probable that the infection and immunization of
autoantigens in NOD-mice stimulates of cytokine release and of APC function (Lund & Strid,
2000). This then leads to generation of functional immunoregulatory cells capable of sup-
pressing the diabetogenic process. Several β-cell autoantigens have been reported to postpone
or prevent diabetes in NOD-mice (Daniel & Wegmann, 1996; Elias et al., 1991;  Hutchings &
Cooke, 1998; Kaufman et al., 1993). It has been shown, however, that the route of antigen ad-
ministration and timing of immunization have an effect on the type of Th response generated
(Cooke et al., 2001; Hutchings & Cooke, 1998). In mice, oral immunization with an antigen
results in Th2 immunity, while both Th2 and Th1 are induced after intravenous administration
(Hutchings & Cooke, 1998). In our study, both Th1 and Th2 immune responses were induced
after intraperitoneal admistration of CBV4-E2.
5.5. Cross-reactivity associated with immunization and infections in humans (V)
Enteroviruses may reach pancreatic islets and destroy β-cells by virus-induced cytolysis
(Roivainen et al., 2000; Vuorinen et al., 1992; Yoon et al., 1978). On the other hand, virus-
induced inflammatory reactions may result in β-cell destrucion (Chehadeh et al., 2000; See &
Tilles, 1995; Vreugdenhil et al., 2000b). Alternatively, β-cell destruction may be induced by
cross-reactive immune responses between enteroviruses and islet cell autoantigens (Kaufman
et al., 1992; Lönnrot et al., 1996;  Tian et al., 1994). This later aspect was further studied in
humans. We were especially interested in whether enterovirus infection or poliovirus vaccina-
tion can induce immune responses that could cross-react with islet cell autoantigens. Further-
more, diabetic children and healthy subjects were assayed for islet cell and enterovirus anti-
bodies.
The study showed that during serologically confirmed enterovirus infections antibodies to
known diabetes associated epitopes in pIA-2 or pHSP60 (Table 4) appeared  in 10% and in
1% of cases, respectively. In addition, some patients showed increased antibody levels to hu-
man HSP60 and HSP65/M.bovis proteins. CAV9-infection induced immune responses were
investigated in detail in humans using epitope mapping with overlapping peptides of CAV9
capsid proteins VP1-VP4 and CBV4 2C, GAD65, IA-2, HSP60 and preproinsulin immobi-
lized in peptide spots. We chose CAV9-infected patients based on previous results that CAV9
is a diabetes-associated virus (Roivainen et al., 1998) and infected human β cells in vitro
(Roivainen et al., 2000; Roivainen et al., 2002 in press).
According to our results, humoral immune responses were targeted to two N terminal  and one
C-terminal epitope of  the capsid protein VP1. These regions were also found by CAV9 immu-
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nized rabbit sera (Pulli et al., 1998), but only PALTAVETGHT-sequence of VP1 was recog-
nized by CBV4 immunized NOD-mice. Out of the tested autoantigens by epitope mapping,
the most remarkable change in antibody specificity  during CAV9 infection was the emer-
gence of response against  HSP60 SIQSIVPALEIA peptide, not found in acute infection. The
same epitope was also recognized by CVB4-E2 immunized NOD-mice. The search for viral
sequence (Blast sequence comparison-program), possibly inducing this cross-reaction, did not
provide  any good candidate. CAV9 infection was not shown to change the reactivity pattern
against other autoantigens.
The individual sera of diabetic patients and healthy controls were assayed for antibodies to
VP1-, VP0-, IA-2- and HSP60-peptides (Table 4). Most diabetic patients and controls had
high levels of antibodies to both coxsackievirus-and poliovirus- derived VP1 peptides and
some had a definite reaction with the diabetogenic epitope in IA-2 (pIA-2a), while very low
antibody levels, if any, were directed to HSP60 peptide (pHSP).
Since epitope scanning worked out in recognition of the main B-cell epitopes induced  by
CAV9, we proceeded with our investigation to islet cell autoantigens. The diabetes sera were
divided according to their reactivity to different autoantigens. Sera of control subjects were
further divided to those with high reactivity to VP1 peptides (pVP1a, pVP1b) and to those
with low levels of antibodies to these peptides.
The amino terminal region of VP1 representing the SASPALTAVETGHTSQV region was rec-
ognized by all serum pools from diabetic patient (GADA, IA-2A, IAA and positive for all
three autoantibodies). In many cases, the serum pools originally positive for a certain autoanti-
body did not react with the peptides derived from the corresponding autoantigens. This em-
phasizes the importance of conformational epitopes in β-cell autoantigens. We identified some
linear epitopes derived from autoantigens, which were recognized by serum pools from au-
toantibody positive patients but not by serum pools from healthy children. The reactivity to
these linear epitopes was associated with the presence of multiple autoantibodies in patients
with type 1 diabetes. Many of these epitopes have not been reported to be diabetes associated
B-cell epitopes and the significance of this finding remains open.
We also studied poliovirus-induced responses in poliovirus-vaccinated Finnish children. This
was prompted by our previous results, which indicated that coxsackievirus-derived peptide
antiserum was more cross-reactive with the diabetes-associated IA-2 epitope (ALTAV) than
the corresponding poliovirus-derived peptide antiserum (III). In the present study, children
immunized with three doses of IPV rarely had antibodies to the conserved VP1 epitope of en-
teroviruses. A dose of live poliovirus vaccine increased the reactivity with VP1 peptides but
did not result in cross-reactivity with the diabetes-associated epitope in IA-2 as did natural
enterovirus infection.
45
Figure 2. Positions of identified epitopes IA-2, HSP60 and preproinsulin (PP-insulin) ac-
cording to literatures, and recognized in this study (II, III, IV, V).
IA-2. T-cell epitopes of IA-2 recognized by diabetic patients (Hawkes et al., 2000; Honeyman et al.,
1998; Peakman et al., 1999), upper panel with white background. Epitopes, identified by more than
one group are shown in black and amino acid numbers shown in bold. Lower panel, with yellow back-
ground represents regions identified by us. Blue bars: epitopes of CBV4-E2 immunized NOD-mice;
brown bar: epitope recognized by poliovirus derived VP1 peptide (pVP1b) induced rabbit antiserum,
epitopes recognized by CBV4 induced rabbit antiserum are shown in grey; red bar: epitope recognized
by coxsackievirus derived VP1 peptide (pVP1a) and CBV4 immunized rabbit sera, CBV4-E2 immu-
nized NOD-mice, and by some human sera. Humoral resonses to IA-2 are directed mainly to C termi-
nal end of intracellular proteins, but also to N-terminal and middle part of of the molecule (Leslie et
al., 1999).
HSP60: Diabetes associated epitopes in HSP60 (Bockova et al., 1997; Elias et al., 1990; Horvath et
al., 2002; Raz et al., 2001) (upper panel). The epitopes, identified by more than one group is shown in
black and aa numbers bolded. Lower panel: blue bars: epitopes recognized by sera from CBV4-E2
immunized NOD-mice. The region recognized both by CBV4-E2 immunized NOD mice and by
pVP1a induced rabbit serum is shown in red. B-cell epitopes recognized by sera from diabetic patients
are aa 437-460 (p277) and aa 394-413, the latter showing sequence homology with GAD65 aa 520-
534 (Horvath et al., 2002).
Preproinsulin (PP-insulin)  Panel a: Diabetes associated T-cell epitopes in preproinsulin (Congia et
al., 1998) (aa 11-26, 20-36, 73-90, 85-101 in preproinsulin) shown in green and in proinsulin p24-33
spanning the B chain/C peptide junction shown in red (Chen et al., 2001). The overlapping region of
epitopes are shown in black. Panel b: Insulin specific epitopes, B-chain aa 9-23, A-chain aa 7-21
(Abiru et al., 2001; Daniel & Wegmann, 1996). Region 24-36 in proinsulin has sequence similarity
with GAD65 aa 506-518 (Rudy et al., 1995). Panel c: an epitope 11-25 in PP-insulin recognized by
CBV4-E2 immunized NOD-mice in our study (IV)
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6. GENERAL DISCUSSION AND CONCLUSIONS
Antigenic molecular mimicry is defined by cross-reactive immunity due to structural homolo-
gies shared by molecules encoded by distinct genes. Shared epitope can be based on either
linear amino acid sequence of the molecules or their conformation. Data base searches of pro-
tein sequences derived from mammals and microorganisms reveal many potential epitopes
shared between numerous microbes and host self proteins and which could have rel-
evance to autoimmune disease (Jones et al., 1993; Oldstone, 1998; Wucherpfennig &
Strominger, 1995; Wucherpfennig & Eisenbarth, 2001). Sequence similarity does not neces-
sarily induce cross-reacting immune responses. On the other hand, foreign antigen may not
necessarily share identical amino acid sequences with self protein to drive autoreactive re-
sponses, and such epitopes would not have been identified by sequence alignment alone
(Wucherpfennig & Strominger, 1995). Out of a panel of 129 peptides that matched the mo-
lecular motif  reguired for the MHC class II binding and TCR recognition of
immunodominant myelin basic protein (MBP) peptide, only seven viral and on bacterial pep-
tide stimulated T-cell clones of multiple sclerosis patients. Of these, only one would have been
found by sequence alignment (Wucherpfennig & Strominger, 1995). To be immunologically
important, shared epitopes must be immunogenic, become processed by antigen presenting
cells and induce antibody and T-cell responses. Moreover, to induce T-cell responses peptides
must be bound to HLA molecules, some of which have been shown to be either protective or
susceptible in e.g. type 1 diabetes (Awata et al., 1992; Ilonen et al., 1997).
We found sequence similarity between enteroviruses capsid protein VP1 and  procapsid pro-
tein VP0 with islet autoantigens IA-2/IA-2β and HSP60. These autoantigen epitopes were pre-
viously reported to be important diabetes-associated epitopes both in humans and NOD-mice
(Elias et al., 1991; Honeyman et al., 1998; Horvath et al., 2002; Peakman et al., 1999; Raz et
al., 2001). Furthermore, both of these enterovirus epitopes have been shown to be immuno-
genic and capable to induce both humoral and cellular immune responses during
infection (Huber et al., 1993; Marttila et al., 2002; Roivainen et al., 1991).
This study demonstrates that apart from the well documented sequence homology (PEVKEK)
between coxsackievirus 2C protein and GAD65, there are also other homologies between islet
cell autoantigens and enteroviruses. Among the homologous and potentially cross-reactive
motifs in enteroviruses and different cell autoantigens studied, the cross-reactive immune re-
sponse to pIA-2 and coxsackievirus-derived VP1 peptide, sharing ALTAV sequence, was most
convincing. Peptides derived from homologous motifs were shown to  induce cross-reactive
 immune responses frequently. Moreover, this cross-reaction was not limited to the hyperimmune
sera in rabbits and NOD-mice, but was also observed in humans.
It is important to understand the potential mechanism by which enterovirus infections could be
involved in the etiology of type 1 diabetes. Especially, in order to develop a safe enterovirus
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vaccine the mechanisms by which enteroviruses possibly are involved in β-cell destruction
should be known. If the mechanism is direct β-cell cytolysis (Roivainen et al., 2000; Vuorinen
et al., 1992; Yoon et al., 1978), virus induced inflammatory reactions (Chehadeh et al., 2000;
See & Tilles, 1995) or bystander damage (Horwitz et al., 1998), then vaccination might pre-
vent some enterovirus infections and accordingly possibly some of the diabetes cases. How-
ever, if the mechanism is based on molecular mimicry, then the vaccine itself might increase
the risk developing T1D.
Poliovirus vaccination is considered safe, and it did not induce cross-reactive immune re-
sponses with diabetogenic epitopes studied here. This potential of cross-reactivity between
enteroviruses and islet cell autoantigens should, however, to be taken into account if vaccines
to enteroviruses are to developed.
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